Israeli Biotech Macrocure Sets Terms for $75 Million IPO
Published: Jul 31, 2014
Macrocure, a late-stage Israeli biotech developing white blood cell injections to treat hard-to-heal wounds, announced terms for its IPO on Friday. The Petach Tikva, Israel-based company plans to raise $75 million by offering 5.4 million shares at a price range of $13 to $15. At the midpoint of the proposed range, it would command a fully diluted market value of $264 million.
Help employers find you! Check out all the jobs and post your resume.